We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current RGC market cap is 70.92M. The company's latest EPS is USD -0.3306 and P/E is -16.49.
| Quarter End | |||||
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | |||||
| Operating Income | |||||
| Net Income |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -812k | -1.38M | -7.62M | -6.27M | -4.74M |
| Net Income | -812k | -1.35M | -7.6M | -5.87M | -4.3M |
| Quarter End | |||||
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | |||||
| Total Liabilities | |||||
| Total Equity |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 514k | 340k | 18.02M | 12.62M | 8.44M |
| Total Liabilities | 3.17M | 4.34M | 938k | 633k | 219k |
| Total Equity | -2.65M | -4M | 17.08M | 11.99M | 8.22M |
| Market Cap | 70.92M |
| Price to Earnings Ratio | -16.49 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 23.96 |
| Price to Book Ratio | 8.63 |
| Dividend Yield | - |
| Shares Outstanding | 13.01M |
| Average Volume (1 week) | 23.35k |
| Average Volume (1 Month) | 67.05k |
| 52 Week Change | -47.55% |
| 52 Week High | 32.44 |
| 52 Week Low | 3.00 |
| Spread (Intraday) | 1.23 (19.74%) |
| Company Name | Regencell Bioscience Holdings Ltd |
| Address |
11/f first commercial building hong kong 999077 |
| Website | https://www.regencellbioscience.com |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
